HALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LRCX
6. LVS
7. SAP
8. CSX
9. SPY
10. KNX

Go back to HALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTS

Halozyme Therapeutics (HALO) Tops Q4 EPS by 1c

February 22, 2022 4:02 PM EST

Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.42, $0.01 better than the analyst estimate of $0.41. Revenue for the quarter came in at $102 million versus the consensus estimate of $100.29 million.

GUIDANCE:

Halozyme Therapeutics sees FY2022 EPS of $2.05-$2.20, versus the consensus of $2.18.... More